[{"id":"58500c01-6437-4480-ae01-c2820de938ce","acronym":"DONIMI","url":"https://clinicaltrials.gov/study/NCT04133948","created_at":"2021-01-18T20:11:28.878Z","updated_at":"2024-07-02T16:35:29.174Z","phase":"Phase 1/2","brief_title":"Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma","source_id_and_acronym":"NCT04133948 - DONIMI","lead_sponsor":"The Netherlands Cancer Institute","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • domatinostat (4SC-202)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 01/07/2020","start_date":" 01/07/2020","primary_txt":" Primary completion: 01/11/2022","primary_completion_date":" 01/11/2022","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2023-11-15"},{"id":"e0efd4fc-7269-417c-899d-24b63061a776","acronym":"TURANDOT","url":"https://clinicaltrials.gov/study/NCT04871594","created_at":"2021-05-04T11:52:33.961Z","updated_at":"2024-07-02T16:35:34.242Z","phase":"Phase 1b","brief_title":"Pre-operative Immunotherapy in Stage II-III Urothelial Cancer","source_id_and_acronym":"NCT04871594 - TURANDOT","lead_sponsor":"The Netherlands Cancer Institute","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • domatinostat (4SC-202)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 08/23/2021","start_date":" 08/23/2021","primary_txt":" Primary completion: 06/02/2023","primary_completion_date":" 06/02/2023","study_txt":" Completion: 06/02/2026","study_completion_date":" 06/02/2026","last_update_posted":"2023-10-09"},{"id":"8510abcf-9a1e-4823-bfb7-04eb2abd381d","acronym":"EMERGE","url":"https://clinicaltrials.gov/study/NCT03812796","created_at":"2021-01-18T18:50:37.059Z","updated_at":"2025-02-25T16:08:45.791Z","phase":"Phase 2","brief_title":"Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE)","source_id_and_acronym":"NCT03812796 - EMERGE","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • domatinostat (4SC-202)"],"overall_status":"Unknown status","enrollment":" Enrollment 75","initiation":"Initiation: 01/11/2019","start_date":" 01/11/2019","primary_txt":" Primary completion: 11/30/2021","primary_completion_date":" 11/30/2021","study_txt":" Completion: 11/30/2021","study_completion_date":" 11/30/2021","last_update_posted":"2019-02-05"}]